Experimental autoimmune
orchitis (EAO) is a rodent model of chronic testicular
inflammation that mimics the pathology observed in some types of human
infertility. In a previous study, testicular expression of the inflammatory/immunoregulatory
cytokine,
activin A, was elevated in adult mice during the onset of EAO, indicating a potential role in the regulation of the disease. Consequently, we examined the development of EAO in mice with elevated levels of
follistatin, an endogenous
activin antagonist, as a potential therapeutic approach to testicular
inflammation. Prior to EAO induction, mice received a single
intramuscular injection of a non-replicative recombinant adeno-associated viral vector carrying a gene cassette of the circulating form of
follistatin, FST315 (FST group). Serum
follistatin levels were increased 5-fold in the FST group compared with the control empty vector (EV) group at 30 and 50 days of EAO, but intra-testicular levels of
follistatin or
activin A were not significantly altered. Induction of EAO was reduced, but not prevented, with mild-to-severe damage in 75% of the EV group and 40% of the FST group, at 50 days following immunisation with testicular homogenate. However, the EAO damage score (based on disruption of the blood-testis barrier, apoptosis, testicular damage and
fibrosis) and extent of intratesticular
inflammation (expression of inflammatory mediators) were directly proportional to the levels of
activin A measured in the testis at 50 days. These data implicate
activin A in the progression of EAO, thereby providing a potential therapeutic target; however, elevating circulating
follistatin levels were not sufficient to prevent EAO development.